| REGISTERED NUMBER: |
| Unaudited Financial Statements for the Year Ended 31 October 2024 |
| for |
| Globepharm Limited |
| REGISTERED NUMBER: |
| Unaudited Financial Statements for the Year Ended 31 October 2024 |
| for |
| Globepharm Limited |
| Globepharm Limited (Registered number: 01823324) |
| Contents of the Financial Statements |
| for the Year Ended 31 October 2024 |
| Page |
| Company Information | 1 |
| Balance Sheet | 2 |
| Notes to the Financial Statements | 3 |
| Globepharm Limited |
| Company Information |
| for the Year Ended 31 October 2024 |
| Director: |
| Secretary: |
| Registered office: |
| Registered number: |
| Globepharm Limited (Registered number: 01823324) |
| Balance Sheet |
| 31 October 2024 |
| 2024 | 2023 |
| Notes | £ | £ |
| Total assets less current liabilities |
| Capital and reserves |
| Called up share capital | 5 |
| Retained earnings | ( |
) | ( |
) |
| Shareholders' funds |
| The director acknowledges her responsibilities for: |
| (a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and |
| (b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company. |
| The financial statements were approved by the director and authorised for issue on |
| Globepharm Limited (Registered number: 01823324) |
| Notes to the Financial Statements |
| for the Year Ended 31 October 2024 |
| 1. | Statutory information |
| Globepharm Limited is a |
| 2. | Accounting policies |
| Basis of preparing the financial statements |
| Goodwill |
| Goodwill, being the amount paid in connection with the acquisition of a business, is being amortised evenly over its estimated useful life of 5 years. |
| Intangible assets |
| Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses. |
| Going concern |
| The company has no assets and is reliant on the continuing support of the director. |
| 3. | Employees and directors |
| The average number of employees during the year was NIL (2023 - NIL). |
| 4. | Intangible fixed assets |
| Goodwill |
| £ |
| Cost |
| At 1 November 2023 |
| and 31 October 2024 |
| Amortisation |
| At 1 November 2023 |
| and 31 October 2024 |
| Net book value |
| At 31 October 2024 |
| At 31 October 2023 |
| Globepharm Limited (Registered number: 01823324) |
| Notes to the Financial Statements - continued |
| for the Year Ended 31 October 2024 |
| 5. | Called up share capital |
| Allotted, issued and fully paid: |
| Number: | Class: | Nominal | 2024 | 2023 |
| value: | £ | £ |
| Ordinary | £1.00 | 100 | 100 |